专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

KR101493488B1 신규의 피리딘 유도체 및 이를 이용한 설포닐우레아 제초제의 제조 중간체 화합물의 제조방법 有权
标题翻译：新型吡啶衍生物及其制备用于生产磺酰亚胺除草剂的中间体化合物的方法
公开(公告)号：KR101493488B1
公开(公告)日：2015-02-16
申请号：KR1020130052600
申请日：2013-05-09
申请人： 주식회사 엘지생명과학
发明人： 안세창 , 김숙희 , 이주영 , 윤주용 , 윤만영
IPC分类号： C07D213/61 , A01N43/34
CPC分类号： C07D213/70 , A01N47/36 , C07D213/61 , C07D213/71
摘要： 본 발명은 우수한 제초활성을 나타내는 플루오로알킬피리딘-설포닐우레아 유도체를 제조하기 위한 핵심 중간체 화합물의 새로운 제조방법, 그리고 이때 사용된 신규 피리딘 유도체 및 이의 제조방법에 관한 것으로, 본 발명에 따른 화학식 (3)의 신규 피리딘 유도체 화합물을 이용하는 방법에 의하면, 플루세토설푸론의 제조 중간체인 화학식 (2)의 화합물을 간단한 공정에 의해 높은 수율로 제조할 수 있다.
[화학식 2]

[화학식 3]

상기 식에서, A, D, E 및 Y는 발명의 상세한 설명에 정의된 바와 같다.

2. 发明公开

KR1020140001648A 안정성이 개선된 클로피도그렐 황산수소염의 경구용 제제 제품 无效
标题翻译：口服剂型硫酸氢盐产品具有改善的稳定性
公开(公告)号：KR1020140001648A
公开(公告)日：2014-01-07
申请号：KR1020120069868
申请日：2012-06-28
申请人： 주식회사 엘지생명과학
发明人： 황우신 , 김근태 , 박성재 , 윤주용 , 정재연
IPC分类号： A61K9/20 , A61K31/4743 , A61K9/16
CPC分类号： A61K31/4365 , A61K9/1623 , A61K9/1652 , A61K9/2054
摘要： The present invention relates to an oral medicine product containing clopidogrel hydrogen sulfate with improved stability, more specifically to an oral medicine product containing clopidogrel hydrogen sulfate which is sealed and packed with an oxygen absorbent, and is capable of controlling the production and increase of impurities by increasing the oxidation stability of the clopidogrel hydrogen sulfate.
摘要翻译：本发明涉及含有硫酸氢氯吡格雷的口服药物，其具有改善的稳定性，更具体地涉及密封并填充有氧吸收剂的硫酸氢氯吡格雷的口服药物，并且能够通过以下方式控制杂质的产生和增加增加硫酸氢氯吡格雷的氧化稳定性。

3. 发明公开

KR1020030080509A 우레아, 티오우레아 및 설파마이드 유도체를 함유하는항균제 조성물 无效
标题翻译：含有尿素，硫脲和磺酰胺衍生物的抗菌剂组合物
公开(公告)号：KR1020030080509A
公开(公告)日：2003-10-17
申请号：KR1020020019177
申请日：2002-04-09
申请人： 주식회사 엘지생명과학
发明人： 윤주용 , 김원섭 , 이현호 , 임재홍 , 이석원 , 윤승현 , 송정욱 , 김종엽 , 최성필 , 윤하식 , 조양래
IPC分类号： A61K31/18
摘要： PURPOSE: An antibacterial agent composition containing urea, thiourea and sulfamide derivatives as an effective ingredient is provided. Therefore, it shows antimicrobial activity and an antibacterial spectrum against wide pathogens containing various Gram positive bacteria and thus is expected to be useful in the prevention and treatment of animal disease caused by bacterial infection. CONSTITUTION: The antibacterial agent composition contains urea, thiourea, sulfamide derivatives and a pharmaceutically acceptable salt, hydrate and solvate thereof represented by the formula I. In formula, each of X and Y is hydrogen, chlorine or trifluoromethyl, Z is -CO-, -CS- or -SO2-. Therefore, it exhibits excellent antibacterial activity against methicillin-resistant Staphylococcus aureus. It can be administered in the form of injectable formulations or oral formulations.
摘要翻译：目的：提供含有脲，硫脲和磺酰胺衍生物作为有效成分的抗菌剂组合物。因此，它表现出抗菌活性和对含有各种革兰氏阳性菌的广病原体的抗菌谱，因此预期可用于预防和治疗由细菌感染引起的动物疾病。构成：抗菌剂组合物含有式I所示的尿素，硫脲，磺酰胺衍生物及其药学上可接受的盐，水合物和溶剂合物。在式中，X和Y各自为氢，氯或三氟甲基，Z为-CO-， -CS-或-SO 2 - 。因此，对耐甲氧西林金黄色葡萄球菌具有优异的抗菌活性。其可以以可注射制剂或口服制剂的形式施用。

4. 发明公开

KR1020030064970A 신규 살리실아닐라이드 유도체 및 그를 함유하는 항균제조성물 无效
标题翻译：新型磺胺衍生物和抗生素组合物
公开(公告)号：KR1020030064970A
公开(公告)日：2003-08-06
申请号：KR1020020005069
申请日：2002-01-29
申请人： 주식회사 엘지생명과학
发明人： 윤승현 , 김원섭 , 이현호 , 임재홍 , 윤주용 , 김종엽 , 송정욱 , 이석원 , 최성필 , 바실리아티모프 , 윤하식 , 조양래
IPC分类号： C07D213/75
摘要： PURPOSE: Provided are novel salicylanilide derivatives represented by formula 1 which are useful as antibiotic against methicillin resistant Staphylococcus aureus(MRSA), their pharmaceutically acceptable non toxic salts, their biologically hydrolyzable ester, hydrate, solution product and their isomers. CONSTITUTION: The novel salicylanilide derivatives are represented by formula 1, wherein R is hydrogen, C1-6 alkyl, C1-3 alkoxy, acetyl or benzyl; X and Y are independently hydrogen, halogen, amino or nitro; Z is nitrogen, oxygen, sulfur, -O-(CH2)m-, -(CH2)m-O-, sulfone or sulfonamino where m is an integer of 1 to 3; A is I, V, W substituted hetero aryl containing Q2, V, W substituted bicyclic hetero aryl containing Q2 and Q3 and I, W substituted indane containing Q2, Q3, Q4 where Q1, Q2, Q3 and Q4 are each independently, one selected from N, C and S; G, J, I, V, W are each independently hydrogen, C1-6 alkyl substituted or non-substituted by halogen, C3-6 cyclo alkyl, C1-6 alkoxy, hydroxy, halogen, cyano, nitro, sulfone sulfonamide, hydroxy carbonyl, C1-6alkoxy carbonyl, C6-8 aryl, C5-8 hetero aryl substituted or non-substituted by halogen, which contains one or two atom selected from N, O and S, or C2-9 hetero aryl oxy substituted or non-substituted by halogen, which contains one or two atom selected from N, O and S. The compounds of formula 1 is synthesized by reacting compounds of formula 2 with compounds of formula 3 in a solvent in presence of base and catalyst. In the formula 2 and 3, R, X, Y, Z, A, Q1, G and J are the same as above.
摘要翻译：目的：提供由式1表示的新型水杨酰苯胺衍生物，其可用作耐甲氧西林金黄色葡萄球菌（MRSA），其药学上可接受的无毒盐，其生物可水解酯，水合物，溶液产物及其异构体的抗生素。构成：新型水杨酰苯胺衍生物由式1表示，其中R是氢，C 1-6烷基，C 1-3烷氧基，乙酰基或苄基; X和Y独立地是氢，卤素，氨基或硝基; Z是氮，氧，硫，-O-（CH 2）m - ， - （CH 2）m -O-，砜或磺氨基，其中m是1至3的整数; A是I，V，W取代的含有Q2的杂芳基，V，含有Q2和Q3的W取代的双环杂芳基和I，含有Q 2，Q 3，Q 4的W取代的二氢化茚，其中Q1，Q2，Q3和Q4各自独立地选自来自N，C和S; G，J，I，V，W各自独立地为氢，被卤素取代或不被取代的C 1-6烷基，C 3-6环烷基，C 1-6烷氧基，羟基，卤素，氰基，硝基，砜磺酰胺，羟基羰基取代或未被卤素取代的C 1-6烷氧基羰基，C 6-8芳基，C 5-8杂芳基，其含有一个或两个选自N，O和S的原子，或C 2-9杂芳氧基取代或未取代的通过卤素，其含有一个或两个选自N，O和S的原子。式1的化合物通过在碱和催化剂存在下在溶剂中使式2化合物与式3化合物反应来合成。在式2和3中，R，X，Y，Z，A，Q 1，G和J与上述相同。

5. 发明公开

KR1020140009016A 신규의 피리딘 유도체 및 이를 이용한 설포닐우레아 제초제의 제조 중간체 화합물의 제조방법 有权
标题翻译：新型吡啶衍生物及其制备用于生产磺酰亚胺除草剂的中间体化合物的方法
公开(公告)号：KR1020140009016A
公开(公告)日：2014-01-22
申请号：KR1020130052600
申请日：2013-05-09
申请人： 주식회사 엘지생명과학
发明人： 안세창 , 김숙희 , 이주영 , 윤주용 , 윤만영
IPC分类号： C07D213/61 , A01N43/34
CPC分类号： C07D213/70 , A01N47/36 , C07D213/61 , C07D213/71
摘要： The present invention relates to a novel method for preparing a core intermediate compound for producing fluoroalkylpyridine-sulfonylurea exhibiting excellent herbicidal activity, a novel pyridine derivative used in the method, and a method for preparing the pyridine derivative. According to the method for using the novel pyridine derivative of Chemical Formula (3) of the present invention, the compound of chemical formula (2), which is an intermediate for preparing flucetosulfuron, can be produced at a high yield by a simple process. [Chemical Formula 2] [Chemical Formula 3] wherein A, D, E, and Y are as defined in the detailed description of the invention.
摘要翻译：本发明涉及制备具有优异除草活性的氟代烷基吡啶磺酰脲的核心中间体化合物的新方法，该方法中所用的新型吡啶衍生物和吡啶衍生物的制备方法。根据本发明的化学式（3）的新型吡啶衍生物的使用方法，可以通过简单的方法以高产率制备作为制备氟嘧磺隆的中间体的化学式（2）化合物。 [化学式2] [化学式3]其中A，D，E和Y如本发明的详细说明中所定义。

6. 发明授权

KR100589964B1 Ｃ형 간염 바이러스의 억제제 失效
标题翻译：丙型肝炎病毒抑制剂
公开(公告)号：KR100589964B1
公开(公告)日：2006-06-19
申请号：KR1020040040967
申请日：2004-06-04
申请人： 주식회사 엘지생명과학
发明人： 김원섭 , 윤주용 , 임재홍 , 송정욱 , 성이택 , 강승완 , 송호영 , 김용주 , 최성필 , 김종엽 , 조영규 , 김창명 , 박지현
IPC分类号： C07D239/22 , A61K31/505
CPC分类号： C07D239/22 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04
摘要： 본 발명은 C형 간염의 치료 및 예방에 유용한 신규의 화합물, 이 화합물을 제조하는 방법, 및 이 화합물을 활성성분으로서 함유함을 특징으로 하는 C형 간염의 치료 및 예방용 조성물에 관한 것이다.

7. 发明授权

KR101424013B1 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법 有权
标题翻译： 1-（3-氰基-1-异丙基 - 吲哚-5-基）吡唑-4-甲酸晶形及其制备方法
公开(公告)号：KR101424013B1
公开(公告)日：2014-08-18
申请号：KR1020120035349
申请日：2012-04-05
申请人： 주식회사 엘지생명과학
发明人： 윤정민 , 박기숙 , 윤주용 , 이주영 , 김근태 , 정철규
IPC分类号： C07D403/04 , A61K31/4155 , A61P3/00 , A61P9/00
CPC分类号： C07D403/04
摘要： 본 발명은 하기 식 1 화합물의 결정형과 그의 제조방법에 관한 것이다.
[화학식 1]

8. 发明公开

KR1020120114174A 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산의 결정형과 그의 제조방법 有权
标题翻译： 1-（3-氰基-1-异丙基吲哚-5-基）吡唑-4-羧酸结晶形式及其制备方法
公开(公告)号：KR1020120114174A
公开(公告)日：2012-10-16
申请号：KR1020120035349
申请日：2012-04-05
申请人： 주식회사 엘지생명과학
发明人： 윤정민 , 박기숙 , 윤주용 , 이주영 , 김근태 , 정철규
IPC分类号： C07D403/04 , A61K31/4155 , A61P3/00 , A61P9/00
CPC分类号： C07D403/04
摘要： PURPOSE: A crystalline form of a compound and a method for preparing the same are provided to selectively suppress xanthine oxidase and to ensure thermal stability and storage stability. CONSTITUTION: A crystalline form of 1-(3-cyano-1-isopropyl-indole-5-yl)pyrazole-4-carboxylic acid is denoted by formula 1. A method for preparing the crystalline form of the compound of formula 1 comprises a step of dissolving the compound of chemical formula 1 in a solvent and crystallizing. The solvent includes anhydrous ethanol, 2-methoxy ethanol, isobutanol, n-butanol, n-octanol, n-propanol, isopropanol, t-butanol, acetic acid, acetone, butyl acetate, methyl acetate, ethyl acetate, propyl acetate, t-butyl acetate, isobutyl acetate, methyl ethyl ketone, 2-pentanone, tetrahydrofurane, acetonitrile, chloroform, toluene, or a mixture thereof.
摘要翻译：目的：提供化合物的结晶形式及其制备方法以选择性地抑制黄嘌呤氧化酶并确保热稳定性和储存稳定性。组成：1-（3-氰基-1-异丙基 - 吲哚-5-基）吡唑-4-羧酸的结晶形式由式1表示。制备式1化合物的结晶形式的方法包括将化学式1的化合物溶解在溶剂中并结晶的步骤。溶剂包括无水乙醇，2-甲氧基乙醇，异丁醇，正丁醇，正辛醇，正丙醇，异丙醇，叔丁醇，乙酸，丙酮，乙酸丁酯，乙酸甲酯，乙酸乙酯，乙酸丙酯，乙酸丁酯，乙酸异丁酯，甲基乙基酮，2-戊酮，四氢呋喃，乙腈，氯仿，甲苯或其混合物。

9. 发明公开

KR1020040107367A Ｃ형 간염 바이러스의 억제제 失效
标题翻译： HEPATITIS C病毒抑制剂用于预防和治疗丙型肝炎病毒感染
公开(公告)号：KR1020040107367A
公开(公告)日：2004-12-20
申请号：KR1020040040967
申请日：2004-06-04
申请人： 주식회사 엘지생명과학
发明人： 김원섭 , 윤주용 , 임재홍 , 송정욱 , 성이택 , 강승완 , 송호영 , 김용주 , 최성필 , 김종엽 , 조영규 , 김창명 , 박지현
IPC分类号： C07D239/22 , A61K31/505
CPC分类号： C07D239/22 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07D495/04 , C07D513/04
摘要： PURPOSE: A novel hepatitis C virus inhibitor is provided which is useful for the prevention and treatment of hepatitis C virus infection. Also, provided are a preparation method thereof and a composition for the prevention and treatment of hepatitis C virus containing the same. CONSTITUTION: The hepatitis C virus inhibitor represented by the formula(1), or pharmaceutically acceptable salts, hydrates, solvates and tautomers thereof are provided, wherein X is O or S; R1 is hydrogen, alkyl which is optionally substituted with 1 to 3 substituents selected from halogen, alkoxy, alkoxycarbonyl, hydroxy, carboxy and aryl, alkoxy, alkoxycarbonyl optionally substituted with aryl, or aryl; R2 and R3 are independently hydrogen, alkyl which is optionally substituted with 1 to 3 substituents selected from halogen, hydroxy, alkoxy, alkylsulfonyl and aralkyloxy, alkoxycarbonyl, alkylsulfonylalkyl, aryl or heteroaryl; R5 is alkyl optionally substituted amino, alkylamino which is optionally substituted with alkylcarbonylamino, alkylcarbonyloxy or dialkylamino; alkoxy which is optionally substituted with 1 to 3 substituents selected from benzoyloxy, alkoxycarbonyl, alkyl, alkylsulfonyl, alkylcarbonylthio, alkoxycarbonylamino, and alkyl and oxo, and is optionally substituted with 1 to 3 substituents of heterocycle containing a double bond, aryl optionally substituted carboxy, or aralkyl optionally substituted with alkylcarbonyloxy; R6 is alkyl; R4 is alkyl which is optionally substituted with 1 to 3 substituents selected from alkoxy optionally substituted with heteroaryl, carboxy, alkylthio, alkoxycarbonyl, alkylaminocarbonyl, biphenyl, aryl, aryloxy, aralkyloxy, alkylaryl, amino optionally substituted with alkyl or alkylaryl, cycloalkyl, cycloalkyloxy, alkylaryl sulfonyl, heteroaryl optionally substituted with halogen and heteroarylthio, alkenyl which is optionally substituted with 1 to 3 substituents selected from halogen, aryl and heteroaryl, alkynyl which is optionally substituted with 1 to 3 substituents selected from alkoxy, alkenyloxy, alkynyloxy, aralkyloxy, aryl and heteroaryl, -(CH2)N-cycloalkyl, -(CH2)N-cycloalkenyl, -(CH2)N-aryl, -(CH2)N-heterocycle or -(CH2)N-heteroaryl in which N is an integer of 1 to 10 and -CH2- group is optionally substituted with halogen when N is not 0.
摘要翻译：目的：提供一种新型丙型肝炎病毒抑制剂，可用于预防和治疗丙型肝炎病毒感染。此外，还提供了其预防和治疗含有该丙型肝炎病毒的丙型肝炎病毒的制备方法和组合物。构成：提供由式（1）表示的丙型肝炎病毒抑制剂或其药学上可接受的盐，水合物，溶剂化物和互变异构体，其中X为O或S; R 1为氢，任选被1至3个选自卤素，烷氧基，烷氧基羰基，羟基，羧基和芳基的取代基取代的烷基，烷氧基，任选被芳基取代的烷氧羰基或芳基; R2和R3独立地是氢，任选被1至3个选自卤素，羟基，烷氧基，烷基磺酰基和芳烷氧基，烷氧基羰基，烷基磺酰基烷基，芳基或杂芳基的取代基取代的烷基; R5是烷基任选取代的氨基，任选被烷基羰基氨基，烷基羰基氧基或二烷基氨基取代的烷基氨基; 任选被1至3个选自苯甲酰氧基，烷氧基羰基，烷基，烷基磺酰基，烷基羰硫基，烷氧基羰基氨基和烷基和氧代的取代基取代的烷氧基，并且任选被1至3个含有双键的杂环取代基，或任选被烷基羰基氧基取代的芳烷基; R6是烷基; 羧基，烷硫基，烷氧基羰基，烷基氨基羰基，联苯基，芳基，芳氧基，芳烷氧基，烷基芳基，任选被烷基或烷基芳基取代的氨基，环烷基，环烷基氧基，烷基芳基磺酰基，任选被卤素和杂芳硫基取代的杂芳基，任选被1至3个选自卤素，芳基和杂芳基的取代基取代的烯基，任选被1至3个选自烷氧基，烯氧基，炔氧基，芳烷氧基，芳基和（CH 2）N-环烯基， - （CH 2）N - 环烯基， - （CH 2）N - 芳基， - （CH 2）N - 杂环或 - （CH 2）当N不为0时，-CH 2 - 基团任选被卤素取代。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式